CA3154064A1 - The salts of a compound and the crystalline forms thereof - Google Patents

The salts of a compound and the crystalline forms thereof Download PDF

Info

Publication number
CA3154064A1
CA3154064A1 CA3154064A CA3154064A CA3154064A1 CA 3154064 A1 CA3154064 A1 CA 3154064A1 CA 3154064 A CA3154064 A CA 3154064A CA 3154064 A CA3154064 A CA 3154064A CA 3154064 A1 CA3154064 A1 CA 3154064A1
Authority
CA
Canada
Prior art keywords
compound
crystalline forms
salts
same
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3154064A
Other languages
English (en)
French (fr)
Inventor
Wenji Li
Ling Feng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchmed Ltd
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Publication of CA3154064A1 publication Critical patent/CA3154064A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3154064A 2019-10-14 2020-10-13 The salts of a compound and the crystalline forms thereof Pending CA3154064A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910973785 2019-10-14
CN201910973785.3 2019-10-14
PCT/CN2020/120594 WO2021073494A1 (en) 2019-10-14 2020-10-13 The salts of a compound and the crystalline forms thereof

Publications (1)

Publication Number Publication Date
CA3154064A1 true CA3154064A1 (en) 2021-04-22

Family

ID=75537486

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3154064A Pending CA3154064A1 (en) 2019-10-14 2020-10-13 The salts of a compound and the crystalline forms thereof

Country Status (14)

Country Link
US (1) US12559472B2 (enExample)
EP (1) EP4045484A4 (enExample)
JP (2) JP2022552329A (enExample)
KR (1) KR20220088712A (enExample)
CN (3) CN114555558B (enExample)
AR (1) AR120202A1 (enExample)
AU (1) AU2020367905A1 (enExample)
BR (1) BR112022007035A2 (enExample)
CA (1) CA3154064A1 (enExample)
IL (1) IL292206B2 (enExample)
MX (1) MX2022004274A (enExample)
TW (1) TWI895290B (enExample)
UA (1) UA129777C2 (enExample)
WO (1) WO2021073494A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022411531B2 (en) * 2021-12-13 2025-01-16 Abbisko Therapeutics Co., Ltd. Fgfr4 inhibitor acid salt, preparation method therefor, and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
US20160052926A1 (en) * 2013-03-15 2016-02-25 Hutchison Medipharma Limited Novel pyrimidine and pyridine compounds and usage thereof
CN107660200B (zh) * 2015-04-14 2022-01-11 卫材R&D管理有限公司 结晶fgfr4抑制剂化合物和其用途
TW201833112A (zh) * 2016-12-01 2018-09-16 大陸商和記黃埔醫藥（上海）有限公司 化合物的晶型

Also Published As

Publication number Publication date
JP2025143319A (ja) 2025-10-01
CN119462616A (zh) 2025-02-18
CN114555558B (zh) 2024-12-17
IL292206A (en) 2022-06-01
BR112022007035A2 (pt) 2022-06-28
US12559472B2 (en) 2026-02-24
WO2021073494A1 (en) 2021-04-22
IL292206B2 (en) 2026-03-01
EP4045484A4 (en) 2023-09-06
AR120202A1 (es) 2022-02-02
KR20220088712A (ko) 2022-06-28
TWI895290B (zh) 2025-09-01
AU2020367905A1 (en) 2022-04-21
JP2022552329A (ja) 2022-12-15
CN114555558A (zh) 2022-05-27
US20230121346A1 (en) 2023-04-20
TW202128669A (zh) 2021-08-01
UA129777C2 (uk) 2025-07-30
IL292206B1 (en) 2025-11-01
EP4045484A1 (en) 2022-08-24
CN119751422A (zh) 2025-04-04
MX2022004274A (es) 2022-05-06

Similar Documents

Publication Publication Date Title
AU2021323253A8 (en) Heterocyclic GLP-1 agonists
ZA202206923B (en) New methylquinazolinone derivatives
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
WO2020016749A3 (en) Chemical process for preparing phenylpiperidinyl indole derivatives
EP4541422A3 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
WO2019165043A3 (en) Indane-amines as pd-l1 antagonists
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
PH12022550832A1 (en) ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS.
AU2018256227A1 (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
AU2001280438A1 (en) Substituted heterocyclic amides
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
PH12022550531A1 (en) Irak inhibitor and preparation method therefor and use thereof
PH12022551241A1 (en) Egfr inhibitors
AU2019375825A8 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
ZA202106815B (en) Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
ZA202106437B (en) Compound form having enhanced bioavailability and formulations thereof
WO2022104153A3 (en) Compounds and methods for treating viral infections
ZA202105887B (en) Selective inhibitor of protein arginine methyltransferase 5 (prmt5)
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
AU2010321366A8 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
WO2023150592A3 (en) N3-substituted uracil compounds as trpa1 inhibitors
MX2022004274A (es) Las sales de un compuesto y sus formas cristalinas.
WO2023150291A3 (en) Heterocyclic compounds and methods of use
CA3156320A1 (en) 2-AZASPIRO[3,4] OCTANE DERIVATIVES USED AS M4 AGONISTS

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241004

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241004

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241004

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241011

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241011

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241011

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241015

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241216

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241216

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250424

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250429

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251003

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251003

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20251027

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251104

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260302